Various Advancements in the Drug Development Technologies are Beholding the Growth of Presbyopia Therapeutics Pipeline | Top Key Players are Novartis, ViewPoint Therapeutics, Allergan
Download the sample report at: https://www.pharmaproff.com/request-sample/1233
Presbyopia can be diagnosed through a general refraction assessment with the help of dilation. Moreover, due to unavailability of approved therapies in the market, use of eyeglasses, contact lenses, and surgery can treat presbyopia. Among these, eyeglasses and contact lenses are most frequently used for the management of various types of ophthalmic disorders including presbyopia.
Browse Detailed Report at: https://www.pharmaproff.com/report/presbyopia-therapeutics-pipeline-analysis
According to the research, most of pipeline therapeutic drug candidates are being developed for topical administration. It is observed that the topical administration is the most effective method of treatment. It is easy to use, non-invasive, and ensures high level of patient satisfaction.
Companies that are developing therapeutics for presbyopia have shown positive clinical results in various phases of drug development. For instance, in July 2018, Presbyopia Therapies LLC reported that its topical PRX ophthalmic solution met primary efficacy and safety endpoints in a phase IIb study. Similarly, in May 2016, Encore Vision Inc. (now acquired by Novartis International AG) announced phase I/II study positive results of EV06 ophthalmic solution. This drug candidate is first-in-class, being targeted for softening of stiffened lenses.
Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1233
In the wake of strategic development activities, company like Novartis International AG acquired Encore Vision to expand its portfolio of topical treatment candidate of presbyopia.
Some of the key players involved in the development of drugs for presbyopia are Novartis International AG, Presbyopia Therapies LLC, ViewPoint Therapeutics Inc., Allergan plc, Cellix Biosciences Inc., and others.
Toll-free: +1-888-778-7886 (USA/Canada)
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Various Advancements in the Drug Development Technologies are Beholding the Growth of Presbyopia Therapeutics Pipeline | Top Key Players are Novartis, ViewPoint Therapeutics, Allergan here
News-ID: 1766722 • Views: 488
More Releases from Pharma Proff
Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: https://www.pharmaproff.com/request-sample/1189 Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances
More Releases for Presbyopia
Global Presbyopia Correction Devices Market 2019 - AcuFocus, Refocus, Presbia
This new report by Eon Market Research, titled “Global Presbyopia Correction Devices Market 2019 Research Report, 2015 – 2025” offers a comprehensive analysis of Presbyopia Correction Devices industry at a global as well as regional and country level. Key facts analyzed in this report include the Presbyopia Correction Devices market size by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025. This report primarily focuses
Presbyopia Market Growth And Restrain Factors Analysis H1 2017
Overview Presbyopia is an eye condition in which eye slowly loses the ability to focus quickly on objects that are close. Presbyopia happens in people as they age. Signs and symptoms include headaches, eyestrain, difficulty reading small print and fatigue. Risk factors include anemia, diabetes, cardiovascular disease, hyperopia, multiple sclerosis, myasthenia gravis and eye trauma. Click here for sample report @ http://www.wiseguyreports.com/sample-request/1555348-presbyopia-pipeline-review-h1-2017 Report Highlights The Presbyopia (Ophthalmology) pipeline guide also reviews of key players
Presbyopia Therapeutics Pipeline Analysis 2018
Presbyopia Pipeline Analysis The study analyzed that the presbyopia therapeutics pipeline comprises nine drug candidates in different stages of development. Presbyopia is an age-related eye condition that causes visual impairment gradually. The disease has been described as "an irreversible optical failure, an unexplained evolutionary blunder that comes as a psychologic shock”. Though not incapacitating if corrected, presbyopia without optical correction results in an inability to perform once-effortless near tasks at a
Presbyopia - Pipeline Review, H2 2017 - MarketResearchReports.
"The Report Presbyopia - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Presbyopia - Pipeline Review, H2 2017, provides an overview of the Presbyopia (Ophthalmology) pipeline landscape. Presbyopia is an eye condition in which eye slowly loses the ability to focus quickly on objects that are close. Presbyopia happens
Presbyopia - Pipeline Review, H1 2017
Report Hive Market Research Released a New Research Report of 30 pages on Title " Presbyopia - Pipeline Review, H1 2017 "with detailed Analysis, Forecast and Strategies. Presbyopia - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Presbyopia - Pipeline Review, H1 2017, provides an overview of the Presbyopia (Ophthalmology) pipeline landscape. Presbyopia is an eye condition in which eye slowly loses the ability to focus quickly
Asia-Pacific Presbyopia Correction Device Market Report 2017
MarketResearchReports.Biz presents this most up-to-date research on "Asia-Pacific Presbyopia Correction Device Market Report 2017" Description In this report, the Asia-Pacific Presbyopia Correction Device market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split Asia-Pacific into several key Regions, with sales (K Units), revenue (Million USD), market share